Document Detail


Alfuzosin for the treatment of storage symptoms suggestive of overactive bladder.
MedLine Citation:
PMID:  22594844     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
INTRODUCTION: Antimuscarinics are the mainstay of overactive bladder (OAB) pharmacotherapy although other agents, such as α-adrenergic receptor antagonists, might also be effective. Alfuzosin has α1-adrenoreceptor antagonist activity and is available worldwide for the treatment of lower urinary tract symptoms resulting from benign prostate hyperplasia. Alfuzosin may relieve storage symptoms suggestive of OAB in patients with or without bladder outlet obstruction (BOO).
AREAS COVERED: This paper reviews the available literature on the use of alfuzosin in the treatment of storage symptoms suggestive of OAB. Additionally, the role of α-adrenoreceptor antagonists in the treatment of OAB is reviewed, based on pathophysiology.
EXPERT OPINION: Although alfuzosin is effective against storage symptoms, it does not improve them in all patients with OAB. It is likely that alternative types of therapy, such as antimuscrarinics, need to be co-administered to patients with residual storage symptoms after alfuzosin administration. Alfuzosin can decrease the risk of adverse events associated with antimuscarinics. The sequential use of alfuzosin and antimuscarinics appears to be an appropriate strategy for the treatment of storage symptoms suggestive of OAB related to BOO.
Authors:
Kang Jun Cho; Joon Chul Kim
Related Documents :
11737404 - Does an hiv clinical trial information booklet improve patient knowledge and understand...
22638994 - Health-related quality of life with kdqol-36 and its association with self-efficacy and...
7313934 - Alternatives to classic randomized trials.
22433994 - Objective measures of physical functional capacity warrant exploration to complement or...
23983954 - Varenicline-induced psychotic depressive episode in a patient with bipolar disorder.
9160564 - Pilot study of a cckb antagonist in patients with panic disorder: preliminary findings.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Expert opinion on pharmacotherapy     Volume:  13     ISSN:  1744-7666     ISO Abbreviation:  Expert Opin Pharmacother     Publication Date:  2012 Jun 
Date Detail:
Created Date:  2012-05-18     Completed Date:  2012-09-11     Revised Date:  2014-07-31    
Medline Journal Info:
Nlm Unique ID:  100897346     Medline TA:  Expert Opin Pharmacother     Country:  England    
Other Details:
Languages:  eng     Pagination:  1143-51     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adrenergic alpha-Antagonists / therapeutic use*
Animals
Humans
Quinazolines / therapeutic use*
Urinary Bladder, Overactive / drug therapy*
Chemical
Reg. No./Substance:
0/Adrenergic alpha-Antagonists; 0/Quinazolines; 90347YTW5F/alfuzosin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A Pilot Study for Targeted Surveillance of Bovine Spongiform Encephalopathy in Nigeria.
Next Document:  Targeting reperfusion injury in acute myocardial infarction: a review of reperfusion injury pharmaco...